| Wissenschaftl. Titel | A phase 3 multicenter, randomized, prospective, open-label trial of -fixed-duration (12 months) Venetoclax/Obinutuzumab vs.-fixed-duration (15 months) Venetoclax/Pirtobrutinib vs.-MRD-guided Venetoclax/Pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL)/smalllymphocytic lymphoma (SLL) aiming to establish Measurement Of Individual Residualdisease for Adaption of treatment duration to Improve outcome. (MOIRAI) |
| Erkrankung |
Blut:
Non-Hodgkin-Lymphome (NHL), niedrig-maligne:
Chronische lymphatische Leukämie (CLL) - sonstige Studien
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 19.12.2025 Admin02
geändert 23.12.2025 Admin07